Method for diagnosing brucella infection

Brucella is a facultative intracellular pathogenic bacterium responsible for brucellosis, a worldwide re-emerging zoonotic disease affecting wildlife and livestock. Brucella can be transmitted to humans via contaminated food or infected aerosol particles, thereby leading to undulant fever followed by chronic devastating multi-organ inflammation if untreated. By RNA-seq analysis of blood of patient cohorts from Spain and Macedonia, the inventors have identified SLAMF1 as a biomarker of the acute phase of Brucella infection in humans. In addition, cytokine analysis led us to define a set of four serum biomarkers (IL-10, IL1RA, CXCL1 and IL-7) for Brucella chronicity. SLAMF1 is an immune cell receptor expressed notably at the surface of dendritic cells (DC), lymphocytes and haematopoietic stem cells and involved in the control of immune responses. Thus the present invention relates to the detection of Brucella infection and the stratification of the patients (those with acute phase or chronic phase of the infection).

Keywords: Brucella infection, differnetial diagnostic, acute infection, chronic infection, relapse infection
Patent Application number: EP 20 306 104.9 on 28/09/2020
PCT/EP2021/076534 on 27/09/2021
Publications:
Cell Microbiol 2020 Apr 22 Degos et al. Omp25-dependent engagement of SLAMF1 by Brucella abortus in dendritic cells limits acute inflammation and favours bacterial persistence in vivo doi: 10.1111/cmi.13164.

Reference:

BIO19142-D1

Business Developper
contact
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2020-09-28

You might also be interested in